Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Maine PFAS Fund redirects $200,000 to publish and share cholestyramine treatment protocols
Summary
Advisory committee agreed to reallocate $200,000 originally set aside for designing a clinical trial toward supporting two Maine clinicians to refine, publish and disseminate cholestyramine treatment protocols and case series to increase clinician access to the treatment.
The Maine PFAS advisory committee agreed to redirect $200,000 that had been earmarked to design a clinical trial toward supporting clinicians who are using cholestyramine to reduce PFAS levels in patients’ blood, members said at a department meeting.
The transfer is meant to support two Maine clinicians who have developed institutional protocols — a family medicine physician at Reddington Fairview General Hospital in Skowhegan and a pediatrician at Maine Medical Center in Portland — so they can refine those protocols and publish case series documenting outcomes, Maine CDC and DACF staff said. Isaac Benowitz, chief medical officer and state epidemiologist at Maine CDC, described the plan during the meeting: "So we're proposing to do to use the allocated $200,000 to do 2 things. The first is to provide support to the 2 clinicians that I mentioned earlier so they can improve their treatment protocols and make those protocols and indirectly make…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
